Sequenom Inc (SQNM) 1.10 $SQNM
Sequenom Files Patent Infringement Lawsuit in Australia
PR Newswire - Tue Jun 07, 7:30AM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it filed a patent infringement lawsuit in Australia. The patent relates to the detection of cell-free fetal DNA for non-invasive prenatal testing (NIPT).
SQNM: 1.10 (-0.09)
Sequenom to Present at Jefferies Global Healthcare Conference
PR Newswire - Thu Jun 02, 1:37PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the Company's participation at the Jefferies 2016 Global Healthcare Conference in New York, NY on June 10, 2016.
SQNM: 1.10 (-0.09)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 40.86 (-1.39), SQNM: 1.10 (-0.09), TSRO: 44.34 (-0.83), NKTR: 14.70 (-0.84)
Sequenom, Inc. Reports First Quarter 2016 Results
PR Newswire - Wed May 04, 3:03PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today reported total revenues of $27.6 million, total accessioned units of 46,400, and a net loss of $13.4 million, or $0.11 per basic and diluted share, for the first quarter of 2016.
SQNM: 1.10 (-0.09)
Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for Georgia, Indiana, Kentucky, Missouri, Ohio, Virginia and Wisconsin
PR Newswire - Tue May 03, 6:01PM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into agreements with Blue Cross and Blue Shield of Georgia, Inc. (effective 4/11/16), Anthem Blue Cross and Blue Shield Health Plans for Indiana, Kentucky, Missouri, Ohio and Wisconsin (effective 5/15), and Anthem Blue Cross and Blue Shield in Virginia (effective 5/23/16).
SQNM: 1.10 (-0.09)
Sequenom Completes Consolidation of North Carolina Operations
PR Newswire - Tue Apr 19, 3:02PM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the completion of the previously-announced consolidation of Sequenom Laboratories(TM) North Carolina operations into its San Diego laboratory facility.
SQNM: 1.10 (-0.09)
Sequenom Strengthens Executive Team with New Vice President of Sales
PR Newswire - Tue Apr 12, 3:03PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, is pleased to announce that Glenn Magnuson has joined the Company as Vice President of Sales, reporting to Rob Lozuk, Senior Vice President, Commercial Operations. Mr. Magnuson has more than 25 years of experience in implementing effective sales processes, strategically managing accounts and realizing the revenue potential of medical diagnostic devices.
SQNM: 1.10 (-0.09)
Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for Connecticut, Maine, and New Hampshire
PR Newswire - Wed Mar 23, 6:45AM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that its wholly owned subsidiary, Sequenom Laboratories(TM), has entered into agreements with Anthem Blue Cross and Blue Shield Health Plans for the states of Connecticut, Maine, and New Hampshire, effective March 28, 2016.
SQNM: 1.10 (-0.09)
Sequenom Files Petition With the Supreme Court of the United States Requesting Review Of Decision On '540 Patent
PR Newswire - Mon Mar 21, 3:05PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced that it filed a petition today with the Supreme Court of the United States to review decisions by lower Federal courts that the claims of Sequenom's U.S. Patent No. 6,258,540 ("'540 Patent"
are not patent eligible under the patent eligibility criteria established by the Supreme Court's Mayo Collaborative Services v. Prometheus Laboratories decision. In the petition, Sequenom urges the Court to hear the case because the Court is uniquely suited to reconcile and interpret the patent eligibility criteria established in its Mayo decision. Those overly-expansive patent eligibility criteria have not only negatively impacted Sequenom's patent, but have put into jeopardy the patentability of existing and future diagnostic method patent claims.
SQNM: 1.10 (-0.09), RXDX: 5.13 (unch)
Four Biotechs To Consider On Intermediate Bottom, Trend Change Signal
ACCESSWIRE - Mon Mar 14, 9:10AM CDT
NEW YORK, NY / ACCESSWIRE / March 14, 2016 / 2015 was a wild year in biotech, with six months of sector-wide gains during January to July reversed throughout the latter half of the year on a combination of political reform expectations and US rate-hike-induced risk-off sentiment. We're nearly a full quarter into 2016, and it looks like we may have finally seen an intermediate bottom in stocks with yesterday's big up move holding today, March 2.
SQNM: 1.10 (-0.09), CDTX: 10.43 (-0.47), ATHX: 1.92 (-0.08)
Sequenom Announces Contract with Anthem BlueCross
PR Newswire - Wed Mar 02, 3:39PM CST
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced the completion of an agreement with Anthem BlueCross. The agreement provides in-network coverage for Anthem's California customers for Sequenom Laboratories' noninvasive prenatal tests in both high and average risk pregnancies, beginning March 1, 2016.
SQNM: 1.10 (-0.09)
Sequenom reports 4Q loss
Automated Insights - Wed Mar 02, 3:17PM CST
SAN DIEGO (AP) _ Sequenom Inc. (SQNM) on Wednesday reported a fourth-quarter loss of $12.2 million, after reporting a profit in the same period a year earlier.
SQNM: 1.10 (-0.09)
Sequenom, Inc. Reports 2015 Financial Results
PR Newswire - Wed Mar 02, 3:05PM CST
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today reported results for the fourth quarter and full year 2015.
SQNM: 1.10 (-0.09)
Can The Uptrend Continue for Sequenom (SQNM)?
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 7:24AM CST
Investors certainly have to be happy with Sequenom Inc. (SQNM) and its short term performance
SQNM: 1.10 (-0.09)
Sequenom Files Patent Infringement Lawsuit in Australia
PR Newswire - Tue Jun 07, 7:30AM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it filed a patent infringement lawsuit in Australia. The patent relates to the detection of cell-free fetal DNA for non-invasive prenatal testing (NIPT).
SQNM: 1.10 (-0.09)
Sequenom to Present at Jefferies Global Healthcare Conference
PR Newswire - Thu Jun 02, 1:37PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the Company's participation at the Jefferies 2016 Global Healthcare Conference in New York, NY on June 10, 2016.
SQNM: 1.10 (-0.09)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 40.86 (-1.39), SQNM: 1.10 (-0.09), TSRO: 44.34 (-0.83), NKTR: 14.70 (-0.84)
Sequenom, Inc. Reports First Quarter 2016 Results
PR Newswire - Wed May 04, 3:03PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today reported total revenues of $27.6 million, total accessioned units of 46,400, and a net loss of $13.4 million, or $0.11 per basic and diluted share, for the first quarter of 2016.
SQNM: 1.10 (-0.09)
Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for Georgia, Indiana, Kentucky, Missouri, Ohio, Virginia and Wisconsin
PR Newswire - Tue May 03, 6:01PM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into agreements with Blue Cross and Blue Shield of Georgia, Inc. (effective 4/11/16), Anthem Blue Cross and Blue Shield Health Plans for Indiana, Kentucky, Missouri, Ohio and Wisconsin (effective 5/15), and Anthem Blue Cross and Blue Shield in Virginia (effective 5/23/16).
SQNM: 1.10 (-0.09)
Sequenom Completes Consolidation of North Carolina Operations
PR Newswire - Tue Apr 19, 3:02PM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the completion of the previously-announced consolidation of Sequenom Laboratories(TM) North Carolina operations into its San Diego laboratory facility.
SQNM: 1.10 (-0.09)
Sequenom Strengthens Executive Team with New Vice President of Sales
PR Newswire - Tue Apr 12, 3:03PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, is pleased to announce that Glenn Magnuson has joined the Company as Vice President of Sales, reporting to Rob Lozuk, Senior Vice President, Commercial Operations. Mr. Magnuson has more than 25 years of experience in implementing effective sales processes, strategically managing accounts and realizing the revenue potential of medical diagnostic devices.
SQNM: 1.10 (-0.09)
Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for Connecticut, Maine, and New Hampshire
PR Newswire - Wed Mar 23, 6:45AM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that its wholly owned subsidiary, Sequenom Laboratories(TM), has entered into agreements with Anthem Blue Cross and Blue Shield Health Plans for the states of Connecticut, Maine, and New Hampshire, effective March 28, 2016.
SQNM: 1.10 (-0.09)
Sequenom Files Petition With the Supreme Court of the United States Requesting Review Of Decision On '540 Patent
PR Newswire - Mon Mar 21, 3:05PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced that it filed a petition today with the Supreme Court of the United States to review decisions by lower Federal courts that the claims of Sequenom's U.S. Patent No. 6,258,540 ("'540 Patent"
are not patent eligible under the patent eligibility criteria established by the Supreme Court's Mayo Collaborative Services v. Prometheus Laboratories decision. In the petition, Sequenom urges the Court to hear the case because the Court is uniquely suited to reconcile and interpret the patent eligibility criteria established in its Mayo decision. Those overly-expansive patent eligibility criteria have not only negatively impacted Sequenom's patent, but have put into jeopardy the patentability of existing and future diagnostic method patent claims. SQNM: 1.10 (-0.09), RXDX: 5.13 (unch)
Four Biotechs To Consider On Intermediate Bottom, Trend Change Signal
ACCESSWIRE - Mon Mar 14, 9:10AM CDT
NEW YORK, NY / ACCESSWIRE / March 14, 2016 / 2015 was a wild year in biotech, with six months of sector-wide gains during January to July reversed throughout the latter half of the year on a combination of political reform expectations and US rate-hike-induced risk-off sentiment. We're nearly a full quarter into 2016, and it looks like we may have finally seen an intermediate bottom in stocks with yesterday's big up move holding today, March 2.
SQNM: 1.10 (-0.09), CDTX: 10.43 (-0.47), ATHX: 1.92 (-0.08)
Sequenom Announces Contract with Anthem BlueCross
PR Newswire - Wed Mar 02, 3:39PM CST
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced the completion of an agreement with Anthem BlueCross. The agreement provides in-network coverage for Anthem's California customers for Sequenom Laboratories' noninvasive prenatal tests in both high and average risk pregnancies, beginning March 1, 2016.
SQNM: 1.10 (-0.09)
Sequenom reports 4Q loss
Automated Insights - Wed Mar 02, 3:17PM CST
SAN DIEGO (AP) _ Sequenom Inc. (SQNM) on Wednesday reported a fourth-quarter loss of $12.2 million, after reporting a profit in the same period a year earlier.
SQNM: 1.10 (-0.09)
Sequenom, Inc. Reports 2015 Financial Results
PR Newswire - Wed Mar 02, 3:05PM CST
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today reported results for the fourth quarter and full year 2015.
SQNM: 1.10 (-0.09)
Can The Uptrend Continue for Sequenom (SQNM)?
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 7:24AM CST
Investors certainly have to be happy with Sequenom Inc. (SQNM) and its short term performance
SQNM: 1.10 (-0.09)
